Page last updated: 2024-10-25

ci 994 and Thrombopenia

ci 994 has been researched along with Thrombopenia in 1 studies

tacedinaline: oral cytostatic drug with impressive differential activity against leukemic cells & normal stem-cells
tacedinaline : A benzamide obtained by formal condensation of the carboxy group of 4-acetamidobenzoic acid with one of the amino groups of 1,2-phenylenediamine. An oral cytostatic drug with impressive differential activity against leukemic cells and normal stem-cells. Also used in combination therapy for selected tumors including non-smoll cell lung, pancreatic, breast, and colorectal cancers.

Research Excerpts

ExcerptRelevanceReference
"Capecitabine was administered in twice daily divided doses, and CI-994 was given as a single daily dose."2.71A phase I study of the oral combination of CI-994, a putative histone deacetylase inhibitor, and capecitabine. ( Janisch, L; Kimmel, KA; Kindler, HL; Macek, TA; Olson, SC; Ratain, MJ; Schilsky, RL; Undevia, SD; Vogelzang, NJ, 2004)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Undevia, SD1
Kindler, HL1
Janisch, L1
Olson, SC1
Schilsky, RL1
Vogelzang, NJ1
Kimmel, KA1
Macek, TA1
Ratain, MJ1

Trials

1 trial available for ci 994 and Thrombopenia

ArticleYear
A phase I study of the oral combination of CI-994, a putative histone deacetylase inhibitor, and capecitabine.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2004, Volume: 15, Issue:11

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols

2004